{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Olaya-Abril A"],"pubmed_abstract":["Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates, especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage independent of serotype and lowering production costs. In this study, we have applied the \"shaving\" proteomic approach, consisting of the LC/MS/MS analysis of peptides generated by protease treatment "],"journal":["PloS one"],"pagination":["e70365"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3720901"],"repository":["biostudies-literature"],"pubmed_title":["Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults."],"pmcid":["PMC3720901"],"pubmed_authors":["Jimenez-Munguia I","Gomez-Gascon L","Obando I","Rodriguez-Ortega MJ","Olaya-Abril A"],"additional_accession":[]},"is_claimable":false,"name":"Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults.","description":"Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates, especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage independent of serotype and lowering production costs. In this study, we have applied the \"shaving\" proteomic approach, consisting of the LC/MS/MS analysis of peptides generated by protease treatment ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013","modification":"2025-04-26T20:26:05.228Z","creation":"2019-03-26T23:15:12Z"},"accession":"S-EPMC3720901","cross_references":{"pubmed":["23894641"],"doi":["10.1371/journal.pone.0070365"]}}